B cells play a more sinister role than believed in progression of type 1 diabetes

A recent study by Vanderbilt Health researchers has revealed a greater, detrimental role for B lymphocytes (B cells) in the ...

ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lun…

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA ...
Frontiers

Novel therapeutic targets in autoimmune diseases: intestinal microbiota and adaptive immunity regulation

Autoimmune diseases comprise more than 80 different diseases that have in common a burden on health systems and are of unknown etiology. In general, in most countries, autoimmune diseases affect an ...
Seeking Alpha

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (IBRX), a leading immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Expanded Access ...
Morning Overview on MSN

Scientists find a way to turbocharge cancer-fighting immunity

Cancer immunotherapy has already transformed treatment for some patients, yet too often the body’s defenders stall out before ...